Form 4: Neumora Therapeutics President Transfers Shares to Family LLC, Retains Control

Joshua Pinto, President of Neumora Therapeutics, Inc., transferred 13,202 shares of common stock to a family limited liability company, maintaining investment control.

Summary

• Joshua Pinto, President of Neumora Therapeutics, Inc. (NMRA), reported a transaction on May 21, 2025, involving the company's common stock.
• He transferred 13,202 shares of Common Stock to a family limited liability company, identified as Maple DE Holdings LLC.
• The transaction was reported with a price of $0, indicating a non-sale disposition (Transaction Code 'G').
• Following this transfer, Mr. Pinto directly owns 63,750 shares and indirectly owns 152,167 shares through the Family LLC.
• Mr. Pinto explicitly stated that he continues to exercise investment control over the Common Stock held by the Family LLC.
• The transaction is noted as exempt from reporting pursuant to Rule 16a-13.

Sentiment

Score: 6

Explanation: The filing reports a non-sale transfer of shares by an insider to a family entity, with the insider retaining investment control. This is generally a neutral to slightly positive signal as it does not indicate divestment and suggests continued long-term interest.

Positives

• The reporting person, Joshua Pinto, maintains investment control over the transferred shares, indicating continued alignment of interests with the company.
• The transaction is a transfer to a family entity rather than a sale, suggesting no immediate intent to divest personal holdings.

Negatives

• No negative financial implications or divestment of shares by the insider were reported in this filing.

Risks

• No specific risks related to the company's operations or financial health were disclosed in this Form 4 filing, as it pertains solely to an insider share transfer.

Future Outlook

This Form 4 filing, detailing an insider share transfer, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The filing indicates that Joshua Pinto continues to exercise investment control over the Common Stock held by the Family LLC.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• Transfer of 13,202 shares of Common Stock by Joshua Pinto to Maple DE Holdings LLC, which is identified as a family limited liability company.

Stakeholder Impact

• Shareholders: The transfer of shares to a family LLC by a key executive, while retaining investment control, suggests continued long-term interest in the company's performance, which is generally a neutral to slightly positive signal.

Key Dates

Recommendation

Keywords

Neumora Therapeutics, NMRA, Joshua Pinto, Form 4, insider transaction, common stock, share transfer, beneficial ownership